177 related articles for article (PubMed ID: 30538442)
41. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
Yi YS; Ban WH; Sohng KY
BMC Cancer; 2018 Oct; 18(1):1053. PubMed ID: 30373585
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of pulmonary resection in non-small cell lung cancer patients older than 70 years old.
Tantraworasin A; Siwachat S; Tanatip N; Lertprasertsuke N; Kongkarnka S; Euathrongchit J; Wannasopha Y; Suksombooncharoen T; Chewaskulyong B; Taioli E; Saeteng S
Asian J Surg; 2020 Jan; 43(1):154-165. PubMed ID: 30898491
[TBL] [Abstract][Full Text] [Related]
43. Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients.
Cheng B; Cai XJ; Chen LY; Wang Z; Weng L; Li QL
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C84-8. PubMed ID: 26323932
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer.
Yamanashi K; Okumura N; Yamamoto Y; Takahashi A; Nakashima T; Matsuoka T; Kameyama K
Asian Cardiovasc Thorac Ann; 2017 Jun; 25(5):371-377. PubMed ID: 28592139
[TBL] [Abstract][Full Text] [Related]
45. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
46. Worse Prognosis for Stage IA Lung Cancer Patients with Smoking History and More Severe Chronic Obstructive Pulmonary Disease.
Yoshida Y; Kage H; Murakawa T; Sato Y; Ota S; Fukayama M; Nakajima J
Ann Thorac Cardiovasc Surg; 2015; 21(3):194-200. PubMed ID: 25641032
[TBL] [Abstract][Full Text] [Related]
47. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
48. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
[TBL] [Abstract][Full Text] [Related]
49. Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease.
Bugge A; Lund MB; Brunborg C; Solberg S; Kongerud J
Ann Thorac Surg; 2016 Jun; 101(6):2125-31. PubMed ID: 27016839
[TBL] [Abstract][Full Text] [Related]
50. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
51. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
52. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
53. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Quoix E; Ramlau R; Westeel V; Papai Z; Madroszyk A; Riviere A; Koralewski P; Breton JL; Stoelben E; Braun D; Debieuvre D; Lena H; Buyse M; Chenard MP; Acres B; Lacoste G; Bastien B; Tavernaro A; Bizouarne N; Bonnefoy JY; Limacher JM
Lancet Oncol; 2011 Nov; 12(12):1125-33. PubMed ID: 22019520
[TBL] [Abstract][Full Text] [Related]
56. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
[TBL] [Abstract][Full Text] [Related]
57. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
58. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
Gargiulo P; Arenare L; Gridelli C; Morabito A; Ciardiello F; Gebbia V; Maione P; Spagnuolo A; Palumbo G; Esposito G; Della Corte CM; Morgillo F; Mancuso G; Di Liello R; Gravina A; Schettino C; Di Maio M; Gallo C; Perrone F; Piccirillo MC
BMC Cancer; 2021 May; 21(1):549. PubMed ID: 33985435
[TBL] [Abstract][Full Text] [Related]
60. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
